Vivus Llc patent expiration
1. Qsymia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071537 | VIVUS LLC | Anticonvulsant derivatives useful in treating obesity |
Jun, 2017
(7 years ago) | |
| US7659256 | VIVUS LLC | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(4 years ago) | |
| US7056890 | VIVUS LLC | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(4 years ago) | |
| US7553818 | VIVUS LLC | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(4 years ago) | |
| US7674776 | VIVUS LLC | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(4 years ago) | |
| US8895058 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(3 years from now) | |
| US9011906 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(3 years from now) | |
| US8895057 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(3 years from now) | |
| US9011905 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(3 years from now) | |
| US8580298 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(4 years from now) | |
| US8580299 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 17, 2015 |
| New Patient Population(NPP) | Jun 24, 2025 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight; For chronic weight management in ad...
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of QSYMIA before it's drug patent expiration?
More Information on Dosage
QSYMIA family patents
